Tebentafusp, a bispecific immunotherapeutic agent, is indicated for HLA-A*02:01-positive adult patients with unresectable mUM27 and represents a treatment option for approximately 45 % of mUM patients who are HLA-A*02:01-positive.5 The HEPZATO KIT, recently approved by the FDA based on the results from the FOCUS study, is the only FDA-approved liver-directed treatment for patients with mUM and is not limited by tumor genotype, thus offering broad utility for this indication. The gene discussed is HLA-A; the disease is neoplasm.